Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
TVRD
Stock Latest News
The Fly
Tvardi Therapeutics files $200M mixed securities shelf
3d ago
TVRD
Premium
The Fly
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
14d ago
TVRD
Premium
Ratings
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
1M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
1M ago
TVRD
Premium
The Fly
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
1M ago
TVRD
Premium
The Fly
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
1M ago
TVRD
Premium
The Fly
Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)
1M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting
2M ago
8K
TVRD
Premium
Ratings
Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
3M ago
TVRD
Premium
The Fly
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
3M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
4M ago
8K
TVRD
Premium
The Fly
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
4M ago
TVRD
Premium
Ratings
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
5M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
6M ago
8K
TVRD
Premium
Company Announcements
Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
6M ago
TVRD
Premium
Ratings
Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics
6M ago
TVRD
Premium
The Fly
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
6M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?
6M ago
TVRD
Premium
The Fly
Tvardi downgraded to Market Perform from Outperform at Raymond James
7M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Faces Setback in Phase 2 Trial
7M ago
8K
TVRD
Premium
Ratings
Optimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks
7M ago
TVRD
Premium
The Fly
Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays
7M ago
TVRD
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
